Valoctocogene roxaparvovec (formerly BMN 270) is one of a handful of competitors advancing gene therapies which could transform treatment of haemophilia A and haemophilia B. The FDA’s ...

The CHMP backed a conditional marketing authorisation for Roctavian (valoctocogene roxaparvovec or valrox) for severe haemophilia A in adults without inhibitors – antibodies that make standard ...

Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 ...